Founded in 2008, Castle Biosciences is a leading molecular diagnostics company
focused on improving health through innovative tests that guide patient care.
Our corporate headquarters is in Friendswood, Texas with laboratory facilities
located in Phoenix, Arizona and Pittsburgh, Pennsylvania.
Realizing a large unmet clinical need in disease management, we continuously
strive to evolve and improve, challenging the status quo with scientific
expertise, valuable insights and robust data development.
Our innovative portfolio of commercial and pipeline tests targets unmet
clinical need along the patient care continuum. We currently market six
proprietary tests designed to answer clinical questions and address treatment
plan challenges facing clinicians, with a primary focus in dermatologic,
including our recently launched AdvanceAD-Tx™ test, and
gastroenterological disease.
Our two tests that currently represent our core revenue drivers are 1)
DecisionDx®-Melanoma test for invasive cutaneous melanoma, which is a
proprietary gene expression profile (GEP) test that uses an individual
patient’s tumor biology to predict the risk of metastasis or recurrence,
as well as the risk of sentinel lymph node positivity, independent of
traditional staging factors, and 2) TissueCypher® Barrett’s
Esophagus test, designed to predict future development of esophageal cancer in
patients with Barrett’s esophagus, the only known risk factor for the
development of esophageal cancer.
DecisionDx®-SCC is our GEP test that predicts the risk of metastasis
in high-risk squamous cell carcinoma patients and predicts which patients are
most likely to benefit from adjuvant radiation therapy. DecisionDx®-UM,
the standard of care in uveal melanoma staging, is our GEP test that predicts
the risk of metastasis for patients with uveal melanoma, a rare eye cancer.
MyPath® Melanoma provides a highly accurate, objective result to aid
dermatopathologists and dermatologists in characterizing suspicious pigmented
lesions. AdvanceAD-Tx™ is our 487-GEP test designed to guide
systemic treatment decision making in patients ages 12 and older with
moderate-to-severe atopic dermatitis, addressing a major unmet need by
providing a personalized approach, helping physicians match patients to the
right treatment class and avoid the trial-and-error process.
Additionally, we have active research and development programs for tests in
these and other diseases with high unmet clinical need, including ongoing
initiatives to increase both our current dermatologic and gastrointestinal
offerings. We also look to put the strength of our balance sheet to work
through a disciplined and strategic approach to capital deployment, focusing
on creating stockholder value.
Learn more about Castle Biosciences' mission to empower patients and healthcare
providers by combining innovation, advanced technologies, and relevant real-world evidence to address
critical unmet clinical needs and improve health outcomes.
This behind-the-scenes video offers an inside look at Castle Biosciences' TissueCypher
testing process, showcasing how advanced imaging, multiplexed biomarker staining, and AI-driven analysis are
utilized to assess a patient's risk of progression from Barrett’s esophagus to esophageal cancer.